Skip to main content

Table 2 Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention

From: Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Strategy Name Cost QALYs Incremental cost-effectiveness ratio ($/QALY)
No vaccine 2379.945 17.71296 (−)
LLR vaccine 2507.851 22.65899 0
Rotarix vaccination 5982.187 24.31454 2105.66
Rotateq vaccination 5577.902 24.44506 1715.14
\